Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

What are the effects of treatment with brentuximab vedotin plus bendamustine on unresponsive HL?

Posted by on Jun 19, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effects of pre-stem cell transplantation (pre-SCT) treatment with brentuximab vedotin (Adcetris) and bendamustine (Treanda) on patients with relapsing/refractory Hodgkin's Lymphoma (HL) following transplant. The main finding was that the drug combination was effective as a pre-SCT therapy. Some...

Read More

What are the long-term effects of stem cell transplant on survival of patients with unresponsive Hodgkin’s lymphoma?

Posted by on Jun 14, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of stem cell transplantation (SCT) on survival in patients with unresponsive Hodgkin’s lymphoma (HL). This study found that SCT was safe and effective in patients with HL that is unrepsonsive to treatment. Some background Hodgkin's Lymphoma is a type of cancer of...

Read More

Is pembrolizumab better than the standard of care in unresponsive Hodgkin’s Lymphoma?

Posted by on Jun 11, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated if pembrolizumab (Keytruda) was more effective than the standard of care in Hodgkin's lymphoma patients unresponsive to brentuximab vedotin (Adcetris). The main finding was that pembrolizumab was more effective than the standard of care in these patients Some background Hodgkin's Lymphoma is...

Read More

Hodgkin lymphoma and thyroid cancer

Posted by on May 31, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined whether Hodgkin lymphoma survivors were more likely to develop more aggressive forms of thyroid cancer than the general population. The authors concluded that a history of Hodgkin lymphoma was not associated with aggressive subtypes or worse outcomes of thyroid cancer. Some background Hodgkin lymphoma survivors are at...

Read More

Is tandem stem cell transplantation effective in high risk relapsed/refractory Hodgkin lymphoma

Posted by on May 26, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effect of tandem stem cell transplantation (SCT) in patients with high-risk relapsed/refractory Hodgkin Lymphoma (HL). The main finding was that patients treated with tandem SCT had greater progression-free survival than those without. Some background A SCT involves the transfer of stem cells into the patient to...

Read More

What are the long-term outcomes for HL patients receiving plerixafor before a stem cell transplant?

Posted by on May 7, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the long-term outcomes of Hodgkin’s lymphoma (HL) patients who received plerixafor (Mozobil) to those who did not prior to autologous stem cell transplantation (autoSCT). This study concluded that plerixafor-treated patients had similar outcomes as patients who received conventional regimens. Some background...

Read More

Does high-dose GBM chemotherapy lead to better post-stem cell transplant outcomes compared to BEAM in refractory or relapsed Hodgkin’s lymphoma patients?

Posted by on May 3, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the outcomes of primary refractory or relapsed Hodgkin’s lymphoma (HL) patients who received GBM (gemcitabine, busulfan, melphalan) or BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy before autoSCT (autologous stem cell transplantation). This study concluded that GBM improved patient outcomes...

Read More